Personalized psychiatry matches therapy to specific patients with depression

May 1, 2017, Elsevier
Predicted probabilities of remission for each treatment at different levels of body mass index (BMI). Credit: Personalized Medicine in Psychiatry

Selecting the antidepressant that will be most effective for a specific patient suffering from depression can be a "try and try again" process. Examining new personalized and precision psychiatry approaches, a new study in Personalized Medicine in Psychiatry shows that body mass index (BMI), sex of the patient, and symptom profile can be used to determine a personalized treatment that guides antidepressant choice and significantly improves patient outcome.

"We are in the midst of a paradigm shift in the field of , to find specific clinical and biological signals that help clinicians and patients decide what is the best treatment," explained lead investigator Leanne Williams, PhD, VA Palo Alto Health Care System and the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine. "This is the shift to incorporate precision medicine approaches to improve outcomes for patients. Our study adds new knowledge to this effort, and does so for two commonly associated chronic conditions, and obesity, that need new treatment approaches. Our results have the potential for a significant impact on the majority of patients suffering from who are seen in primary care and community settlings."

Researchers analyzed data from 659 adults (ages 18-65) with clinical depression who completed the International Study to Predict Optimized Treatment in Depression (iSPOT-D). They were randomly assigned one of three antidepressants (venlafaxine-XR, sertraline, or escitalopram) and followed for eight weeks of treatment. Height and weight were recorded and each participant completed the 17-item Hamilton Rating Scale (a self-reported depression inventory) before and after treatment to measure change in depression severity. Patients who improved so substantially that they were no longer experiencing clinical symptoms were defined as "remitters."

The study found that for both men and women, having a larger BMI than patients of "normal" weight predicted remission for venlafaxine-XR specifically, due to a reduction in physical symptoms, including sleep disturbance, somatic anxiety, and appetite. Females with higher BMI were likely to remit regardless of medication type and this effect was related to a change in cognitive symptoms, including thoughts of suicide and guilt.

These findings are very well suited for immediate translation into the and community settings in which most patients are treated. Primary care doctors have access to information regarding patient sex, BMI (weight relevant to height), along with symptoms of depression.

According to lead author Erin Green, PhD, VA Palo Alto Health Care System and the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, "Although these findings require replication, they are ready for 'prime time' translation into clinical practice where there are currently no indicators and algorithms available for guiding choice for with both depression and obesity."

"The future of psychiatry is in a precision, personalized medicine approach to refining diagnosis and tailoring treatments accordingly. This study demonstrates that currently available markers are poised to improve patient outcomes without introducing new costs. Markers such as BMI are likely to complement others being developed out of neuroimaging and genomics," added Dr. Williams.

Explore further: Brain scans may help clinicians choose talk therapy or medication treatment for depression

More information: Erin Green et al, Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report, Personalized Medicine in Psychiatry (2017). DOI: 10.1016/j.pmip.2016.12.001

Related Stories

Brain scans may help clinicians choose talk therapy or medication treatment for depression

March 24, 2017
Researchers from Emory University have found that specific patterns of activity on brain scans may help clinicians identify whether psychotherapy or antidepressant medication is more likely to help individual patients recover ...

Better prediction for effectiveness of paroxetine

April 13, 2017
A third of patients with depression do not respond to the first antidepressant medication prescribed. Currently, the only approach available is one of trial and error. In this study, Max Planck scientists have identified ...

Blood test unlocks new frontier in treating depression

March 29, 2017
Doctors for the first time can determine which medication is more likely to help a patient overcome depression, according to research that pushes the medical field beyond what has essentially been a guessing game of prescribing ...

Data on depression suggest possibility of personalized treatments

February 23, 2017
Depression is a complex disorder, characterized by clusters of symptoms that respond to treatment with varying degrees of success and are likely to reoccur after initial remission. However, a group of Yale researchers, combing ...

Less than one-third of adults with depression receive treatment

August 29, 2016
New findings suggest that most Americans with depression receive no treatment, while raising the possibility that overtreatment of depression is also widespread. Less than a third of American adults who screened positive ...

Antidepressant efficacy varies for depressive symptom clusters

February 28, 2017
(HealthDay)—Antidepressant treatment efficacy varies for empirically-defined clusters of symptoms, according to a study published online Feb. 22 in JAMA Psychiatry.

Recommended for you

We can read each other's emotions from surprisingly tiny changes in facial color, study finds

March 19, 2018
Our faces broadcast our feelings in living color—even when we don't move a muscle.

Study with infants suggests language not necessary for reasoning ability

March 16, 2018
A team of researchers from Spain, Hungary and Poland has found via a study with infants that language may not be a necessity for the ability to reason. In their paper published in the journal Science, the group describes ...

Hep C compounds alcoholism's effect on brain volume

March 16, 2018
(HealthDay)—Alcohol dependence has deleterious effects on frontal cortical volumes that are compounded by hepatitis C virus (HCV) infection and drug dependence, according to a study published online March 14 in JAMA Psychiatry.

Study casts doubt on ketamine nasal sprays for depression

March 16, 2018
Researchers from the Black Dog Institute and UNSW Sydney have questioned the efficacy and safety of intranasal ketamine for depression, with their pilot trial stopped early due to poor side effects in patients.

Older adults' difficulties with focusing can be used to help put a face to a name

March 16, 2018
Everyone has experienced the awkward situation of meeting someone and then forgetting their name shortly after. Among older adults, this happens more often than not.

A little anger in negotiation pays

March 16, 2018
During negotiations, high-intensity anger elicits smaller concessions than moderate-intensity anger, according to a new study by management and business experts at Rice University and Northwestern University.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.